BRIEF published on 09/15/2025 at 17:55, 8 months 8 days ago Guerbet Revises 2025 Financial Outlook Downward Financial Targets Revenue Decline Guerbet Imaging Solutions 2025 Outlook
BRIEF published on 09/15/2025 at 17:55, 8 months 8 days ago Guerbet révise à la baisse ses perspectives financières pour 2025 Objectifs Financiers Solutions D'imagerie Guerbet Baisse Des Revenus Perspectives 2025
PRESS RELEASE published on 09/15/2025 at 17:50, 8 months 8 days ago Guerbet : Ajustement des objectifs financiers annuels 2025 Guerbet ajuste ses objectifs financiers annuels 2025 avec une légère décroissance du CA et une révision à la baisse de la rentabilité, suite à des challenges en France et aux US Objectifs Financiers Guerbet Imagerie Médicale Décroissance Révision À La Baisse
PRESS RELEASE published on 09/15/2025 at 17:50, 8 months 8 days ago Guerbet : Adjustment of 2025 full-year financial targets Guerbet revises downward its 2025 financial targets due to supply reforms, customer mix shift, and operational issues. Revenue to decline, EBITDA margin revised, and free cash flow expected negative Financial Targets Revenue Decline Guerbet 2025 Downward Revision
BRIEF published on 08/13/2025 at 17:50, 9 months 10 days ago Guerbet : Situation du Capital au 31 Juillet 2025 Droits De Vote Capital Social AMF Guerbet Actions Autodétenues
BRIEF published on 08/13/2025 at 17:50, 9 months 10 days ago Guerbet: Capital Situation as of July 31, 2025 Share Capital Voting Rights AMF Treasury Shares Guerbet
PRESS RELEASE published on 08/13/2025 at 17:45, 9 months 10 days ago GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 juillet 2025 Déclaration du nombre de droits de vote et d'actions composant le capital de la société selon les réglementations en vigueur Capital Droits De Vote Actions AMF Règlement Général
BRIEF published on 05/26/2025 at 08:47, 11 months 28 days ago Guerbet révise son Conseil d'administration Conseil D'administration Nomination Guerbet Administrateur Indépendant Mandat
BRIEF published on 05/26/2025 at 08:47, 11 months 28 days ago Guerbet revises its Board of Directors Board Of Directors Independent Director Appointment Guerbet Mandate
PRESS RELEASE published on 05/26/2025 at 08:42, 11 months 28 days ago Guerbet : Changes in the composition of the Guerbet board of directors. Guerbet reorganizes Board of Directors with appointment and reappointment of independent directors and reduction of terms to 4 years, following the AGM decisions Board Of Directors Reorganization AGM Guerbet Independent Directors
Published on 05/23/2026 at 19:45, 10 hours 37 minutes ago Golden Minerals Announces Closing of Equity Financing
Published on 05/23/2026 at 03:15, 1 day 3 hours ago UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 1 day 3 hours ago Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 1 day 3 hours ago Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 1 day 3 hours ago Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec
Published on 05/24/2026 at 05:55, 26 minutes ago The 26th CIFIT to Open in Xiamen This September, Preceded by Successful Guangzhou Roadshow
Published on 05/24/2026 at 05:35, 46 minutes ago CGTN: Xizang at 75: Development and culture create a 'miracle on Earth'
Published on 05/23/2026 at 16:30, 13 hours 51 minutes ago HiFS 2026: Upgrading Four Major Digital Finance Solutions to Accelerate Financial Institutions Toward Agentic Banking
Published on 05/23/2026 at 15:57, 14 hours 25 minutes ago EQS-Adhoc: Delivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
Published on 05/22/2026 at 22:05, 1 day 8 hours ago Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
Published on 05/22/2026 at 19:35, 1 day 10 hours ago PROJET D'EVOLUTION DE SA GOUVERNANCE ET LA NOMINATION D'UN PRESIDENT DU DIRECTOIRE PAR INTERIM
Published on 05/22/2026 at 18:05, 1 day 12 hours ago Déclaration hebdomadaire d'opérations effectuées du 18 au 22 mai 2026
Published on 05/22/2026 at 18:05, 1 day 12 hours ago Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 1 day 17 hours ago Communiqué du Conseil d’administration – Assemblée Générale du 22 mai 2026
Published on 05/22/2026 at 12:52, 1 day 17 hours ago Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026
